BioStock: Medivir’s CEO comments on the updated clinical data

Medivir continues to make strides with its drug candidate fostrox, targeting primary liver cancer. In the Q3 report published last week, and in a subsequent webcast, the company presented detailed interim data from its phase Ia/IIb study. This data clearly demonstrates increased clinical benefit when fostrox is added to the current standard of care therapy in second-line, Lenvima, compared to Lenvima monotherapy. BioStock reached out to the company's CEO, Jens Lindberg, for a comment on this promising milestone data.

Read the full interview with Medivir's CEO Jens Lindberg at biostock.se:

Medivir’s CEO comments on the updated clinical data - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/